Paramount CEO David Ellison is at the final hurdle before buying WBD. So far, he can't clear it

Paramount Skydance’s $110B bid to acquire Warner Bros. Discovery faces its toughest delay yet as California AG Rob Bonta and 11 state attorneys general push an antitrust case with a March trial date. The closing delay increases Paramount’s costs via “ticking fees” owed to WBD shareholders and has prompted Paramount to seek a court order requiring the suing states to post a $1.88B bond. While regulators have already approved the deal, ongoing negotiations have stalled—Bonta called potential settlement terms “robust structural remedies” and talks reportedly broke down amid allegations of a leaked discussion—leaving uncertainty around whether Paramount must divest pay-TV networks to win approval.

Analysis

This is an option-value leak story more than a pure antitrust story. Every month of delay burns value through fees, legal spend, and management distraction, while the market still prices WBD as if a clean transaction or clean break is equally likely; that asymmetry is usually wrong in contested media deals. If the remedy path requires divesting linear assets, the deal can remain "approved" yet still become economically inferior, because the asset mix that justifies scale is precisely what regulators may force out.

The second-order winner is NFLX, not because it gains directly from this case, but because a weakened or delayed WBD keeps legacy media fragmented, levered, and capital-constrained. That limits the probability of a fast counterweight to streaming leaders and keeps content investment disciplined across the sector; by contrast, WBD remains trapped between declining cash-cow assets and debt service, which is a bad setup for multiple expansion. The more structural risk is that any settlement that clears the case does so by removing the very assets that were supposed to create synergy.

The catalyst window is near-term and event-driven: 4-8 weeks for settlement chatter/judicial headlines, then a hard march toward the trial calendar and fee accruals into month-end dates. The thesis is falsified if there is a credible structural-remedy package that preserves most of the economics or if the court signals a path to rapid clearance; otherwise, the spread should drift wider as time becomes a liability. My base case is that the market is underpricing how bad a "won but gutted" outcome would be for WBD equity.

Key Decisions for Investors

• Short WBD on rallies into legal headline spikes; 1-3 month horizon. Risk/reward favors downside if talks fail or remedies require divestitures, with a clear stop if a credible settlement package emerges.
• Buy WBD put spreads around the next court/settlement window rather than outright puts; use 2-4 month tenor to capture delay economics while limiting premium bleed if headlines whipsaw.
• Pair long NFLX / short WBD for a relative-value hedge on legacy-media regulation risk. The pair benefits if the market re-prices WBD's deal optionality lower while NFLX remains insulated from the transaction overhang.
• If WBD trades materially below the implied deal-adjusted level after any settlement rumor, take profits on shorts quickly; a narrow remedy deal could squeeze the stock even if the long-term economics are impaired.